Outcomes and pulmonary function after sleeve lobectomy compared with pneumonectomy in patients with non–small cell lung cancer
Thoracic Cancer · 2023-03 · 14 (9) · 827-833
DOI: 10.1111/1759-7714.14813 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 02.02.2023. Verfasst von Tsubasa Matsuo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Sleeve lobectomy is recommended to avoid pneumonectomy and preserve pulmonary function in patients with central lung cancer. However, the relationship between postoperative pulmonary functional loss and resected lung parenchyma volume has not been fully characterized. The aim of this study was to evaluate the relationship between pulmonary function and lung volume in patients undergoing sleeve lobectomy or pneumonectomy.
Methods
A total of 61 lung cancer patients who had undergone pneumonectomy or sleeve lobectomy were analyzed retrospectively. Among them, 20 patients performed pulmonary function tests, including vital capacity (VC) and forced expiratory volume in 1 s (FEV1) tests, preoperatively and then about 6 months after surgery. VC and FEV1 ratios were calculated (measured postoperative respiratory function/predicted postoperative respiratory function) as the standardized pulmonary functional loss ratio.
Results
Thirty‐day operation‐related mortality was significantly lower after sleeve lobectomy (3.2%) than pneumonectomy (9.6%). The 5‐year relapse‐free survival rate was 46.67% versus 29.03%, and the 5‐year overall survival rate was 63.33% versus 38.71% in patients receiving sleeve lobectomy versus pneumonectomy. The VC ratio in the pneumonectomy group was better than in the sleeve lobectomy group (1.003 ± 0.117 vs. 0.779 ± 0.12; p = 0.0008), as was the FEV1 ratio (1.132 ± 0.226 vs. 0.851 ± 0.063; p = 0.0038).
Conclusions
Both short‐term and long‐term outcomes were better with sleeve lobectomy than pneumonectomy. However, actual postoperative pulmonary function after pneumonectomy may be better than clinicians expect, and pneumonectomy should still be considered a treatment option for patients with sufficient pulmonary reserve and in whom sleeve lobectomy is less likely to be curative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
- Department of Thoracic Surgery, Iwate Medical University, Yahaba-cho, Japan.
- Department of Health Environmental Science and Public Health, Akita University Graduate School of Medicine, Akita, Japan.
ORCID-Profile: Tsubasa Matsuo, Kazuhiro Imai, Hajime Saito
Zitieren
APA
Matsuo, T., Imai, K., Takashima, S., Kurihara, N., Kuriyama, S., Iwai, H., Tozawa, K., Saito, H., Nomura, K., & Minamiya, Y. (2023). Outcomes and pulmonary function after sleeve lobectomy compared with pneumonectomy in patients with non–small cell lung cancer. Thoracic Cancer, 14(9), 827-833. https://doi.org/10.1111/1759-7714.14813
Vancouver
Matsuo T, Imai K, Takashima S, Kurihara N, Kuriyama S, Iwai H, et al. Outcomes and pulmonary function after sleeve lobectomy compared with pneumonectomy in patients with non–small cell lung cancer. Thoracic Cancer. 2023;14(9):827-833. doi:10.1111/1759-7714.14813
BibTeX
@article{Matsuo2023,
author = {Matsuo, Tsubasa and Imai, Kazuhiro and Takashima, Shinogu and Kurihara, Nobuyasu and Kuriyama, Shoji and Iwai, Hidenobu and Tozawa, Kasumi and Saito, Hajime and Nomura, Kyoko and Minamiya, Yoshihiro},
title = {Outcomes and pulmonary function after sleeve lobectomy compared with pneumonectomy in patients with non–small cell lung cancer},
journal = {Thoracic Cancer},
year = {2023},
volume = {14},
number = {9},
pages = {827--833},
doi = {10.1111/1759-7714.14813}
}
EUVIMED